Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 3/2011

01.09.2011

Late Effects of Childhood Leukemia Therapy

verfasst von: Joy M. Fulbright, Sripriya Raman, Wendy S. McClellan, Keith J. August

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

As survival rates for children treated for childhood cancers become significantly better, the focus is increasingly on determining the late effects of treatments and the best ways to monitor for them and prevent their occurrence. This review focuses on recent literature discussing the late effects of treatment in patients treated for acute myeloid leukemia and acute lymphoblastic leukemia during childhood. The late effects of therapy for childhood leukemia include secondary malignancy, cardiotoxicity, obesity, endocrine abnormalities, reproductive changes, neurocognitive deficits, and psychosocial effects. As clinicians have become more aware of the late effects of therapy, treatment regimens have been changed to decrease late effects, but patients still require long-term follow-up for their prevention and treatment.
Literatur
1.
Leisenring WM, Mertens AC, Armstrong GT, et al. Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2319–27.PubMedCrossRef
2.
Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol. 2002;38:229–39.PubMedCrossRef
3.
Linabery AM, Ross JA. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975–1999. Cancer. 2008;113:2575–96.PubMedCrossRef
4.
Bhatia S, Sather HN, Pabustan OB, et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood. 2002;99:4257–64.PubMedCrossRef
5.
Borgmann A, Zinn C, Hartmann R, et al. Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer. 2008;44:257–68.PubMedCrossRef
6.
Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood. 2008;111:5515–23.PubMedCrossRef
7.
Pui CH, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349:640–9.PubMedCrossRef
8.
Hijiya N, Hudson MM, Lensing S, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007;297:1207–15.PubMedCrossRef
9.
• Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009; 27:2356–62. This report from the CCSS cohort reviews cumulative incidence of SN in ALL/AML survivors 20 and 25 years from therapy. PubMedCrossRef
10.
Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the Children’s Cancer Group studies for childhood acute lymphoblastic leukemia 1983–2002: a Children’s Oncology Group Report. Leukemia. 2010;24:285–97.PubMedCrossRef
11.
Banerjee J, Paakko E, Harila M, et al. Radiation-induced meningiomas: a shadow in the success story of childhood leukemia. Neuro Oncol. 2009;11:543–9.PubMedCrossRef
12.
Bien E, Stachowicz-Stencel T, Szalewska M, et al. Poor-risk high-grade gliomas in three survivors of childhood acute lymphoblastic leukaemia–an overview of causative factors and possible therapeutic options. Childs Nerv Syst. 2009;25:619–26.PubMedCrossRef
13.
• Nathan PC, Wasilewski-Masker K, Janzen LA. Long-term outcomes in survivors of childhood acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009; 23:1065–82, vi-vii. This paper discusses ALL therapy that increases the incidence of SN. It reviews the cumulative incidence of SN 15 years after therapy, as well as risk factors for SN. PubMedCrossRef
14.
15.
Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808–15.PubMedCrossRef
16.
Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16:545–50.PubMed
17.
Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629–36.PubMedCrossRef
18.
Creutzig U, Diekamp S, Zimmermann M, Reinhardt D. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer. 2007;48:651–62.PubMedCrossRef
19.
Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008;100:1368–79.PubMedCrossRef
20.
• Amigoni M, Giannattasio C, Fraschini D, et al. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors. Pediatr Blood Cancer. 2010; 55:1343–47. Children treated for ALL with a mean cumulative dose of 228 mg/m 2 of anthracyclines had reduced LV mass and wall thickness 12.6 years from treatment without clinical symptoms of heart failure. PubMedCrossRef
21.
Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15:1544–52.PubMed
22.
Kremer LC, van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol. 2002;13:503–12.PubMedCrossRef
23.
Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001;19:191–6.PubMed
24.
Kremer LC, van der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002;13:819–29.PubMedCrossRef
25.
Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28:1308–15. This paper highlights the long-term risk of cardiac mortality in children treated with >360 mg/m2 of anthracyclines.PubMedCrossRef
26.
Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer. 2003;97:1991–8.PubMedCrossRef
27.
Sorensen K, Levitt G, Bull C, et al. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997;15:61–8.PubMed
28.
•• Rathe M, Carlsen NL, Oxhoj H, Nielsen G. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010; 54:444–8. This paper describes subclinical echocardiographic changes in a number of parameters in children with ALL treated with lower doses of anthracyclines. PubMedCrossRef
29.
Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145–53.PubMedCrossRef
30.
Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol. 2001;19:3163–72.PubMed
31.
Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738–43.PubMedCrossRef
32.
•• Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010; 11:950–61. In this paper, the beneficial effect of dexrazoxane in children with ALL treated with doxorubicin was demonstrated on echocardiographic follow-up 5 years after treatment, with no change in EFS. PubMedCrossRef
33.
Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007;25:493–500.PubMedCrossRef
34.
Barry EV, Vrooman LM, Dahlberg SE, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008;26:1106–11.PubMedCrossRef
35.
Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91–01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol. 2002;20:1677–82.PubMedCrossRef
36.
Levitt GA, Dorup I, Sorensen K, Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol. 2004;124:463–8.PubMedCrossRef
37.
Steinherz PG, Redner A, Steinherz L, et al. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. Cancer. 1993;72:3120–30.PubMedCrossRef
38.
Erkus B, Demirtas S, Yarpuzlu AA, et al. Early prediction of anthracycline induced cardiotoxicity. Acta Paediatr. 2007;96:506–9.PubMedCrossRef
39.
Hayakawa H, Komada Y, Hirayama M, et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 2001;37:4–9.PubMedCrossRef
40.
Bryant J, Picot J, Baxter L, et al. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer. 2007;43:1959–66.PubMedCrossRef
41.
Rajic V, Aplenc R, Debeljak M, et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma. 2009;50:1693–8.PubMedCrossRef
42.
Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008;112:2789–95.PubMedCrossRef
43.
Cousens P, Waters B, Said J, Stevens M. Cognitive effects of cranial irradiation in leukaemia: a survey and meta-analysis. J Child Psychol Psychiatry. 1988;29:839–52.PubMedCrossRef
44.
• Harila MJ, Winqvist S, Lanning M, et al. Progressive neurocognitive impairment in young adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009; 53:156–61. Patients treated with CRT or chemotherapy alone and healthy controls are compared 20 years after diagnosis. Differences were seen between all three groups in verbal and performance IQ, and between the CRT group and controls for memory, attention, and motor functions. PubMedCrossRef
45.
Peterson CC, Johnson CE, Ramirez LY, et al. A meta-analysis of the neuropsychological sequelae of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;51:99–104.PubMedCrossRef
46.
•• Goldsby RE, Liu Q, Nathan PC, et al. Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010; 28:324–31. This paper highlights the neurologic effects that are seen at a median follow-up of 14.1 years from diagnosis. Increased risk was seen for auditory-vestibular-sensory deficits, coordination and motor problems, headaches, and seizures, compared with siblings. PubMedCrossRef
47.
Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24:5277–82.PubMedCrossRef
48.
Campbell LK, Scaduto M, Sharp W, et al. A meta-analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia. Pediatr Blood Cancer. 2007;49:65–73.PubMedCrossRef
49.
Mitby PA, Robison LL, Whitton JA, et al. Utilization of special education services and educational attainment among long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer. 2003;97:1115–26.PubMedCrossRef
50.
Kingma A, Rammeloo LA, van Der Does-van den Berg A, et al. Academic career after treatment for acute lymphoblastic leukaemia. Arch Dis Child. 2000;82:353–7.PubMedCrossRef
51.
Harila-Saari AH, Lahteenmaki PM, Pukkala E, et al. Scholastic achievements of childhood leukemia patients: a nationwide, register-based study. J Clin Oncol. 2007;25:3518–24.PubMedCrossRef
52.
Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008;9:257–68.PubMedCrossRef
53.
Kadan-Lottick NS, Zeltzer LK, Liu Q, et al. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst. 2010;102:881–93.PubMedCrossRef
54.
Silber JH, Radcliffe J, Peckham V, et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol. 1992;10:1390–6.PubMed
55.
Rubenstein CL, Varni JW, Katz ER. Cognitive functioning in long-term survivors of childhood leukemia: a prospective analysis. J Dev Behav Pediatr. 1990;11:301–5.PubMedCrossRef
56.
Jankovic M, Brouwers P, Valsecchi MG, et al. Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. ISPACC. International Study Group on Psychosocial Aspects of Childhood Cancer. Lancet. 1994;344:224–7.PubMedCrossRef
57.
Waber DP, Tarbell NJ, Kahn CM, et al. The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol. 1992;10:810–7.PubMed
58.
Bleyer WA, Fallavollita J, Robison L, et al. Influence of age, sex, and concurrent intrathecal methotrexate therapy on intellectual function after cranial irradiation during childhood: a report from the Children’s Cancer Study Group. Pediatr Hematol Oncol. 1990;7:329–38.PubMedCrossRef
59.
Waber DP, Gioia G, Paccia J, et al. Sex differences in cognitive processing in children treated with CNS prophylaxis for acute lymphoblastic leukemia. J Pediatr Psychol. 1990;15:105–22.PubMedCrossRef
60.
Jannoun L. Are cognitive and educational development affected by age at which prophylactic therapy is given in acute lymphoblastic leukaemia? Arch Dis Child. 1983;58:953–8.PubMedCrossRef
61.
Moore IM, Kramer JH, Wara W, et al. Cognitive function in children with leukemia. Effect of radiation dose and time since irradiation. Cancer. 1991;68:1913–7.PubMedCrossRef
62.
Moleski M. Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol. 2000;15:603–30.PubMed
63.
Spiegler BJ, Kennedy K, Maze R, et al. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol. 2006;24:3858–64.PubMedCrossRef
64.
Anderson VA, Godber T, Smibert E, et al. Cognitive and academic outcome following cranial irradiation and chemotherapy in children: a longitudinal study. Br J Cancer. 2000;82:255–62.PubMedCrossRef
65.
Langer T, Martus P, Ottensmeier H, et al. CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. Med Pediatr Oncol. 2002;38:320–8.PubMedCrossRef
66.
Butler RW, Hill JM, Steinherz PG, et al. Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. J Clin Oncol. 1994;12:2621–9.PubMed
67.
Anderson V, Smibert E, Ekert H, Godber T. Intellectual, educational, and behavioural sequelae after cranial irradiation and chemotherapy. Arch Dis Child. 1994;70:476–83.PubMedCrossRef
68.
Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003;21:1798–809.PubMedCrossRef
69.
Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:2730–41.PubMedCrossRef
70.
Cole PD, Kamen BA. Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. Ment Retard Dev Disabil Res Rev. 2006;12:174–83.PubMedCrossRef
71.
Kingma A, Van Dommelen RI, Mooyaart EL, et al. No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study. J Pediatr Hematol Oncol. 2002;24:106–14.PubMedCrossRef
72.
Copeland DR, Moore 3rd BD, Francis DJ, et al. Neuropsychologic effects of chemotherapy on children with cancer: a longitudinal study. J Clin Oncol. 1996;14:2826–35.PubMed
73.
Raymond-Speden E, Tripp G, Lawrence B, Holdaway D. Intellectual, neuropsychological, and academic functioning in long-term survivors of leukemia. J Pediatr Psychol. 2000;25:59–68.PubMedCrossRef
74.
• Buizer AI, de Sonneville LM, Veerman AJ. Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: a critical review of the literature. Pediatr Blood Cancer. 2009; 52:447–54. A review of 21 studies found specific deficits in ALL survivors treated without CRT, including deficiencies in attention and executive function. Effects on IQ were not seen in the majority of studies. PubMedCrossRef
75.
Kaemingk KL, Carey ME, Moore IM, et al. Math weaknesses in survivors of acute lymphoblastic leukemia compared to healthy children. Child Neuropsychol. 2004;10:14–23.PubMed
76.
Carey ME, Haut MW, Reminger SL, et al. Reduced frontal white matter volume in long-term childhood leukemia survivors: a voxel-based morphometry study. AJNR Am J Neuroradiol. 2008;29:792–7.PubMedCrossRef
77.
Espy KA, Moore IM, Kaufmann PM, et al. Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study. J Pediatr Psychol. 2001;26:1–9.PubMedCrossRef
78.
Reddick WE, Shan ZY, Glass JO, et al. Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia. Cancer. 2006;106:941–9.PubMedCrossRef
79.
Buizer AI, de Sonneville LM, van den Heuvel-Eibrink MM, Veerman AJ. Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity. Pediatr Blood Cancer. 2005;45:281–90.PubMedCrossRef
80.
Hill DE, Ciesielski KT, Sethre-Hofstad L, et al. Visual and verbal short-term memory deficits in childhood leukemia survivors after intrathecal chemotherapy. J Pediatr Psychol. 1997;22:861–70.PubMedCrossRef
81.
Mulhern RK, Wasserman AL, Fairclough D, Ochs J. Memory function in disease-free survivors of childhood acute lymphocytic leukemia given CNS prophylaxis with or without 1,800 cGy cranial irradiation. J Clin Oncol. 1988;6:315–20.PubMed
82.
Buizer AI, De Sonneville LM, van den Heuvel-Eibrink MM, et al. Visuomotor control in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. J Int Neuropsychol Soc. 2005;11:554–65.PubMedCrossRef
83.
Iuvone L, Mariotti P, Colosimo C, et al. Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia. Cancer. 2002;95:2562–70.PubMedCrossRef
84.
Waber DP, Carpentieri SC, Klar N, et al. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol. 2000;22:206–13.PubMedCrossRef
85.
Kadan-Lottick NS, Brouwers P, Breiger D, et al. A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood. 2009;114:1746–52.PubMedCrossRef
86.
von der Weid N, Mosimann I, Hirt A, et al. Intellectual outcome in children and adolescents with acute lymphoblastic leukaemia treated with chemotherapy alone: age- and sex-related differences. Eur J Cancer. 2003;39:359–65.PubMedCrossRef
87.
Brown RT, Madan-Swain A, Walco GA, et al. Cognitive and academic late effects among children previously treated for acute lymphocytic leukemia receiving chemotherapy as CNS prophylaxis. J Pediatr Psychol. 1998;23:333–40.PubMedCrossRef
88.
• Darzy KH, Shalet SM. Hypopituitarism following radiotherapy revisited. Endocr Dev. 2009; 15:1–24. This is a well-written review of potential hormonal defects in patients who undergo radiation therapy. PubMedCrossRef
89.
Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist. 2004;10:293–310.PubMedCrossRef
90.
Linsenmeier C, Thoennessen D, Negretti L, et al. Total body irradiation (TBI) in pediatric patients. A single-center experience after 30 years of low-dose rate irradiation. Strahlenther Onkol. 2010;186:614–20.PubMedCrossRef
91.
Darzy KH. Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat Clin Pract Endocrinol Metab. 2009;5:88–99.PubMedCrossRef
92.
Haddy TB, Mosher RB, Nunez SB, Reaman GH. Growth hormone deficiency after chemotherapy for acute lymphoblastic leukemia in children who have not received cranial radiation. Pediatr Blood Cancer. 2006;46:258–61.PubMedCrossRef
93.
Viana MB, Vilela MI. Height deficit during and many years after treatment for acute lymphoblastic leukemia in children: a review. Pediatr Blood Cancer. 2008;50:509–16. discussion 517.PubMedCrossRef
94.
Vilela MI, Viana MB. Longitudinal growth and risk factors for growth deficiency in children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;48:86–92.PubMedCrossRef
95.
Alves CH, Kuperman H, Dichtchekenian V, et al. Growth and puberty after treatment for acute lymphoblastic leukemia. Rev Hosp Clin Fac Med Sao Paulo. 2004;59:67–70.PubMedCrossRef
96.
Nandagopal R, Laverdiere C, Mulrooney D, et al. Endocrine late effects of childhood cancer therapy: a report from the Children’s Oncology Group. Horm Res. 2008;69:65–74.PubMedCrossRef
97.
Gurney JG, Ness KK, Sibley SD, et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer. 2006;107:1303–12.PubMedCrossRef
98.
Link K, Moell C, Garwicz S, et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab. 2004;89:5003–12.PubMedCrossRef
99.
Follin C, Thilén U, Osterberg K, et al. Cardiovascular risk, cardiac function, physical activity, and quality of life with and without long-term growth hormone therapy in adult survivors of childhood acute lymphoblastic leukemia. J Clin Endocrinol Metab. 2010;95:3726–35.PubMedCrossRef
100.
Bell J, Parker KL, Swinford RD, et al. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95:167–77.PubMedCrossRef
101.
Chow EJ, Friedman DL, Yasui Y, et al. Timing of menarche among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2008;50:854–8.PubMedCrossRef
102.
van Santen HM, Vulsma T, Dijkgraaf MG, et al. No damaging effect of chemotherapy in addition to radiotherapy on the thyroid axis in young adult survivors of childhood cancer. J Clin Endocrinol Metab. 2003;88:3657–63.PubMedCrossRef
103.
Delvecchio M, Cecinati V, Brescia LP, et al. Thyroid function and thyroid autoimmunity in childhood acute lymphoblastic leukemia off-therapy patients treated only with chemotherapy. J Endocrinol Invest. 2010;33:135–9.PubMed
104.
Bhatti P, Veiga LH, Ronckers CM, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res. 2010;174:741–52.PubMedCrossRef
105.
Einaudi S, Bertorello N, Masera N, et al. Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50:537–41.PubMedCrossRef
106.
Kuperman H, Damiani D, Chrousos GP, et al. Evaluation of the hypothalamic-pituitary-adrenal axis in children with leukemia before and after 6 weeks of high-dose glucocorticoid therapy. J Clin Endocrinol Metab. 2001;86:2993–6.PubMedCrossRef
107.
Kaste SC, Rai SN, Fleming K, et al. Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2006;46:77–87.PubMedCrossRef
108.
• Benmiloud S, Steffens M, Beauloye V, et al. Long-term effects on bone mineral density of different therapeutic schemes for acute lymphoblastic leukemia or non-Hodgkin lymphoma during childhood. Horm Res Paediatr. 2010; 74:241–50. This recent study investigated the effect of leukemia therapy on bone health. It included patients treated with chemotherapy alone, radiation and chemotherapy, and TBI for bone marrow transplantation. PubMedCrossRef
109.
Ross JA, Oeffinger KC, Davies SM, et al. Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2004;22:3558–62.PubMedCrossRef
110.
Dalton VK, Rue M, Silverman LB, et al. Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol. 2003;21:2953–60.PubMedCrossRef
111.
Asner S, Ammann RA, Ozsahin H, et al. Obesity in long-term survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;51:118–22.PubMedCrossRef
112.
Gofman I, Ducore J. Risk factors for the development of obesity in children surviving ALL and NHL. J Pediatr Hematol Oncol. 2009;31:101–7.PubMedCrossRef
113.
Garmey EG, Liu Q, Sklar CA, et al. Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2008;26:4639–45.PubMedCrossRef
114.
Lowas S, Malempati S, Marks D. Body mass index predicts insulin resistance in survivors of pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009;53:58–63.PubMedCrossRef
115.
Marquis A, Kuehni CE, Strippoli MP, et al. Sperm analysis of patients after successful treatment of childhood acute lymphoblastic leukemia with chemotherapy. Pediatr Blood Cancer. 2010;55:208–10.PubMed
116.
Romerius P, Stahl O, Moell C, et al. Hypogonadism risk in men treated for childhood cancer. J Clin Endocrinol Metab. 2009;94:4180–6.PubMedCrossRef
117.
• van Casteren NJ, van der Linden GH, Hakvoort-Cammel FG, et al. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer. 2009; 52:108–12. This study correlates low inhibin B with low sperm concentration. Low inhibin levels were found in childhood cancer survivors. PubMedCrossRef
118.
• Green DM, Kawashima T, Stovall M, et al. Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010; 28:332–9. This large study identified risk factors associated with cancer that place males at increased risk for infertility. PubMedCrossRef
119.
Byrne J, Fears TR, Mills JL, et al. Fertility of long-term male survivors of acute lymphoblastic leukemia diagnosed during childhood. Pediatr Blood Cancer. 2004;42:364–72.PubMedCrossRef
120.
Chemaitilly W, Mertens AC, Mitby P, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006;91:1723–8.PubMedCrossRef
121.
Sklar CA, Mertens AC, Mitby P, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2006;98:890–6.PubMedCrossRef
122.
• Green DM, Kawashima T, Stovall M, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2009; 27:2677–85. This study identifies risk factors associated with cancer that place women at increased risk for reproductive complications, but it also provides reassurance that there was no increased risk for congenital malformation. PubMedCrossRef
123.
Byrne J, Fears TR, Mills JL, et al. Fertility in women treated with cranial radiotherapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2004;42:589–97.PubMedCrossRef
124.
Mueller BA, Chow EJ, Kamineni A, et al. Pregnancy outcomes in female childhood and adolescent cancer survivors: a linked cancer-birth registry analysis. Arch Pediatr Adolesc Med. 2009;163:879–86.PubMedCrossRef
125.
Signorello LB, Cohen SS, Bosetti C, et al. Female survivors of childhood cancer: preterm birth and low birth weight among their children. J Natl Cancer Inst. 2006;98:1453–61.PubMedCrossRef
126.
Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol. 2002;187:1070–80.PubMedCrossRef
127.
Eiser C. Beyond survival: quality of life and follow-up after childhood cancer. J Pediatr Psychol. 2007;32:1140–50.PubMedCrossRef
128.
Pang JW, Friedman DL, Whitton JA, et al. Employment status among adult survivors in the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2008;50:104–10.PubMedCrossRef
129.
Seitzman RL, Glover DA, Meadows AT, et al. Self-concept in adult survivors of childhood acute lymphoblastic leukemia: a cooperative Children’s Cancer Group and National Institutes of Health study. Pediatr Blood Cancer. 2004;42:230–40.PubMedCrossRef
130.
Pakakasama S, Veerakul G, Sosothikul D, et al. Late effects in survivors of childhood acute lymphoblastic leukemia: a study from Thai Pediatric Oncology Group. Int J Hematol. 2010;91:850–4.PubMedCrossRef
131.
• Harila MJ, Salo J, Lanning M, et al. High health-related quality of life among long-term survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010; 55:331–6. This study found that survivors of ALL had a high HRQOL when compared with controls. PubMedCrossRef
132.
Recklitis CJ, Diller LR, Li X, et al. Suicide ideation in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010;28:655–61.PubMedCrossRef
Metadaten
Titel
Late Effects of Childhood Leukemia Therapy
verfasst von
Joy M. Fulbright
Sripriya Raman
Wendy S. McClellan
Keith J. August
Publikationsdatum
01.09.2011
Verlag
Current Science Inc.
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 3/2011
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-011-0094-x

Weitere Artikel der Ausgabe 3/2011

Current Hematologic Malignancy Reports 3/2011 Zur Ausgabe

ReviewPaper

The Unique Characteristics and Management of Patients Over 60 Years of Age with Classic Hodgkin Lymphoma

ReviewPaper

Primary Mediastinal Large B-Cell Lymphoma, Classic Hodgkin Lymphoma Presenting in the Mediastinum, and Mediastinal Gray Zone Lymphoma: What is the Oncologist To Do?

INVITED COMMENTARY

The Importance of Testing PET-Directed Therapy in Patients with Hodgkin Lymphoma

ReviewPaper

The Role of Autologous Transplantation in Hodgkin Lymphoma

ReviewPaper

Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

ReviewPaper

Can Low-Risk, Early-Stage Patients with Hodgkin Lymphoma Be Spared Radiotherapy?

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise